公开(公告)号：US08877194B2

公开(公告)日：2014-11-04

申请号：US13314878

申请日：2011-12-08

Applicant: Chung-ming Hsieh ,  Carrie L. Goodreau ,  Sahana Bose ,  Achim Moeller ,  Tariq Ghayur

Inventor： Chung-ming Hsieh ,  Carrie L. Goodreau ,  Sahana Bose ,  Achim Moeller ,  Tariq Ghayur

IPC: A61K39/395 ,  C07K16/24

CPC classification number: C07K16/241 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/48546 ,  A61K47/6845 ,  A61K49/0058 ,  A61K51/1021 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/14 ,  C07K2317/20 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/624 ,  C07K2317/626 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  G01N33/6863

Abstract: TNF-α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-α are provided. Binding proteins have high affinity for TNF-α and neutralize TNF-α activity. A binding protein can be a full-length antibody or a TNF-α-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-α binding proteins are useful for detecting TNF-α and for inhibiting TNF-α activity, including in a human subject suffering from a disease or disorder in which TNF-α activity is detrimental.

Abstract translation: 提供TNF-α结合蛋白，包括结合TNF-α的嵌合，CDR移植和人源化抗体。 结合蛋白对TNF-α具有高亲和力，并中和TNF-α活性。 结合蛋白可以是全长抗体或其TNF-α结合部分。 还描述了制备方法和使用结合蛋白的方法。 TNF-α结合蛋白可用于检测TNF-α和抑制TNF-α活性，包括在患有TNF-α活性有害的疾病或病症的人类受试者中。

公开(公告)号：US20140178412A1

公开(公告)日：2014-06-26

申请号：US13835537

申请日：2013-03-15

Applicant: Bio-Thera Solutions, Ltd., Co.

Inventor： Chao Qin ,  Shengfeng Li

IPC: A61K47/48 ,  C07D498/14

CPC classification number: A61K47/48561 ,  A61K47/48384 ,  A61K47/48546 ,  A61K47/6803 ,  A61K47/6845 ,  C07D498/14

Abstract: Disclosed herein are anti-EGFR antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat EGFR positive cells in cancers are provided.

Abstract translation: 本文公开了与美登木素生物碱药物缀合的抗EGFR抗体，用于靶向递送至疾病组织。 提供了与这种抗体药物偶联物在癌症中治疗EGFR阳性细胞的制备和用途有关的方法。

公开(公告)号：US20130164816A1

公开(公告)日：2013-06-27

申请号：US13549906

申请日：2012-07-16

Applicant: Chien-Hsing Chang ,  David M. Goldenberg ,  William J. McBride ,  Edmund A. Rossi

Inventor： Chien-Hsing Chang ,  David M. Goldenberg ,  William J. McBride ,  Edmund A. Rossi

IPC: C12N9/96

CPC classification number: A61K47/48438 ,  A61K31/00 ,  A61K38/00 ,  A61K47/48415 ,  A61K47/48484 ,  A61K47/485 ,  A61K47/48538 ,  A61K47/48546 ,  A61K47/48561 ,  A61K47/48569 ,  A61K47/6811 ,  A61K47/6817 ,  A61K47/6829 ,  A61K47/6833 ,  A61K47/6843 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  B82Y5/00 ,  B82Y10/00 ,  B82Y15/00 ,  C07K14/475 ,  C07K16/18 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2881 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/35 ,  C07K2319/70 ,  C07K2319/74 ,  C12N9/12 ,  C12N9/22 ,  C12N9/96 ,  C12Y207/11001 ,  G01N33/54353 ,  G01N33/588 ,  Y02A50/491

Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.

公开(公告)号：US20070086942A1

公开(公告)日：2007-04-19

申请号：US11478021

申请日：2006-06-29

Applicant: Chien Chang ,  David Goldenberg ,  William McBride ,  Edmund Rossi

Inventor： Chien Chang ,  David Goldenberg ,  William McBride ,  Edmund Rossi

IPC: A61K51/00 ,  C12Q1/68 ,  G01N33/53 ,  G01N33/554 ,  C07K16/46

CPC classification number: A61K47/48438 ,  A61K31/00 ,  A61K38/00 ,  A61K47/48415 ,  A61K47/48484 ,  A61K47/485 ,  A61K47/48538 ,  A61K47/48546 ,  A61K47/48561 ,  A61K47/48569 ,  A61K47/6811 ,  A61K47/6817 ,  A61K47/6829 ,  A61K47/6833 ,  A61K47/6843 ,  A61K47/6845 ,  A61K47/6849 ,  A61K47/6851 ,  A61K2039/505 ,  B82Y5/00 ,  B82Y10/00 ,  B82Y15/00 ,  C07K14/475 ,  C07K16/18 ,  C07K16/22 ,  C07K16/28 ,  C07K16/2803 ,  C07K16/2833 ,  C07K16/2851 ,  C07K16/2863 ,  C07K16/2881 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/3007 ,  C07K16/3092 ,  C07K16/32 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/35 ,  C07K2319/70 ,  C07K2319/74 ,  C12N9/12 ,  C12N9/22 ,  C12N9/96 ,  C12Y207/11001 ,  G01N33/54353 ,  G01N33/588 ,  Y02A50/491

Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.

Abstract translation: 本发明涉及用于制备和使用具有多种功能和/或结合特异性的限定组合物的生物活性组合物的方法和组合物。 在特定的实施方案中，生物活性组件使用对接和锁定（DNL）方法形成，其利用二聚化和对接结构域（DDD）和锚定结构域（AD）之间的特异性结合相互作用形成组件。 在各种实施方案中，一个或多个效应物可以连接到DDD或AD序列。 互补AD或DDD序列可以连接到形成生物活性组件核心的适配器模块，从而允许通过特定的DDD / AD结合相互作用形成组装体。 这些组合物可以连接到各种各样的效应部分，用于治疗，检测和/或诊断疾病，病原体感染或其他医学或兽医病症。

公开(公告)号：US6022541A

公开(公告)日：2000-02-08

申请号：US807992

申请日：1997-03-03

Applicant: Donald R. Senger ,  Harold F. Dvorak

Inventor： Donald R. Senger ,  Harold F. Dvorak

IPC: A61K45/00 ,  A61K33/24 ,  A61K38/00 ,  A61K38/43 ,  A61K39/395 ,  A61K41/00 ,  A61K47/48 ,  A61K51/00 ,  A61K51/10 ,  A61P35/00 ,  A61P43/00 ,  C07K16/22 ,  C07K16/24 ,  C12P21/08 ,  A61K49/00 ,  C07K16/18

CPC classification number: A61K51/1021 ,  A61K41/0095 ,  A61K47/48546 ,  A61K47/48753 ,  B82Y5/00 ,  C07K16/22 ,  C07K16/24 ,  A61K2039/507 ,  A61K38/00 ,  C07K2317/34 ,  C07K2319/00

Abstract: The present invention provides an immunological preparation comprising not less than two types of conjugate molecules in admixture for concurrent specific binding to a spatially exposed region of vascular permeability factor (VPF) bound in-vivo to a tumor-associated blood vessel. Each conjugate molecule type comprises at least a binding portion of an antibody specific for an epitope present within a spatially exposed region of bound VPF; and an effector moiety covalently bound to the specific binding portion. The immunological preparation has wide uses and applications including analytical studies, in-vivo diagnostic testing, and in-vivo therapeutic treatments.

Abstract translation: 本发明提供一种免疫学制剂，其包含不少于两种类型的缀合物分子，其混合物用于与肿瘤相关血管体内结合的血管通透性因子（VPF）的空间暴露区域的同时特异性结合。 每个缀合物分子类型至少包含对结合VPF的空间暴露区域内存在的表位具有特异性的抗体的结合部分; 和与特异性结合部分共价结合的效应部分。 免疫学准备具有广泛的应用和应用，包括分析研究，体内诊断测试和体内治疗治疗。

公开(公告)号：US6015558A

公开(公告)日：2000-01-18

申请号：US37777

申请日：1998-03-10

Applicant: Gokhan S. Hotamisligil ,  Bruce M. Spiegelman

Inventor： Gokhan S. Hotamisligil ,  Bruce M. Spiegelman

IPC: C12N15/09 ,  A61K31/52 ,  A61K31/522 ,  A61K38/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/00 ,  A61K47/48 ,  A61P3/08 ,  A61P3/10 ,  A61P43/00 ,  C07K14/715 ,  C07K16/00 ,  C07K16/24 ,  C07K16/28 ,  C12P21/02 ,  C12R1/91

CPC classification number: C07K16/2866 ,  A61K31/52 ,  A61K31/522 ,  A61K47/48546 ,  C07K14/7151 ,  C07K16/00 ,  C07K16/241 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/30 ,  Y10S514/929

Abstract: An induction of TNF-.alpha. mRNA expression has been observed in adipose tissue from four different insulin resistant rodent models of obesity and diabetes. TNF-.alpha. protein was also elevated locally and systemically. Neutralization of TNF-.alpha. in obese fa/fa rats caused a significant increase in the peripheral uptake of glucose in response to insulin. A method of treating an animal suffering from insulin resistance in obesity linked Type II diabetes mellitus is disclosed. The method includes providing a therapeutic agent that includes an antagonist to TNF-.alpha. function in a pharmaceutically acceptable carrier substance and administering a pharmacologically effective amount of the therapeutic agent to the animal.

Abstract translation: 来自四种不同胰岛素抵抗的肥胖和糖尿病啮齿动物模型的脂肪组织观察到TNF-αmRNA表达的诱导。 TNF-α蛋白也在局部和全身升高。 在肥胖的fa / fa大鼠中，TNF-α的中和引起葡萄糖响应于胰岛素的外周摄取显着增加。 公开了一种在肥胖相关的II型糖尿病中治疗患有胰岛素抵抗的动物的方法。 该方法包括提供治疗剂，其包括药学上可接受的载体物质中TNF-α功能的拮抗剂，并向动物施用药理学有效量的治疗剂。

公开(公告)号：US5686600A

公开(公告)日：1997-11-11

申请号：US442542

申请日：1995-05-16

Applicant: Nadine B. Carozzi ,  Michael G. Koziel

Inventor： Nadine B. Carozzi ,  Michael G. Koziel

IPC: A01H5/00 ,  A01N63/02 ,  A61K47/48 ,  C07K14/21 ,  C07K14/325 ,  C07K16/18 ,  C07K19/00 ,  C12N1/21 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  C12N15/13 ,  C12N15/82 ,  C12P21/08 ,  C07H21/04 ,  C07K16/00 ,  C07K16/46

CPC classification number: A01N63/02 ,  A61K47/48438 ,  A61K47/48538 ,  A61K47/48546 ,  A61K47/48561 ,  C07K14/21 ,  C07K14/325 ,  C07K16/18 ,  C07K19/00 ,  C12N15/8286 ,  C07K2317/622 ,  C07K2319/00

Abstract: Antibodies, monoclonal antibodies or fragments thereof which bind to brush border membrane vesicles of insect gut and the gene or genes which encode these proteins are provided. The monoclonal antibodies bind the gut of a target insect but do not bind to mammalian brush border membranes or to plant microsomes. The antibodies and the genes encoding them find use in constructing hybrid toxins for control of insect pests.

Abstract translation: 提供了结合昆虫肠的刷状膜囊泡的抗体，单克隆抗体或其片段以及编码这些蛋白质的基因或基因。 单克隆抗体结合目标昆虫的肠，但不结合哺乳动物刷状膜或植物微粒体。 抗体和编码它们的基因用于构建用于控制害虫的杂交毒素。

公开(公告)号：US5670626A

公开(公告)日：1997-09-23

申请号：US263258

申请日：1994-06-21

Applicant: Tse Wen Chang

Inventor： Tse Wen Chang

IPC: C12N15/09 ,  A61K38/00 ,  A61K39/395 ,  A61K47/48 ,  A61P37/08 ,  C07K16/16 ,  C07K16/18 ,  C07K17/10 ,  C12P21/08 ,  C07K16/14

CPC classification number: C07K16/18 ,  A61K47/48546 ,  A61K38/00

Abstract: Disclosed are pharmaceutical preparations containing human monoclonal IgA antibodies specific for major allergenic proteins found in ragweed, house dust mites, and cat and dog dander. Also disclosed are constructs comprising physiological compatible polymer backbones or microbeads and a plurality of covalently conjugated allergen-specific binding molecules. Such binding molecules are IgG or IgA, or their F(ab').sub.2, Fab, or Fv fragments, specific to the major allergenic proteins mentioned above. Also disclosed are methods for treating a patient with allergic rhinitis, asthma, or conjunctivitis by applying a pharmaceutical preparation containing the antibodies specific for the allergenic molecules, to which the patient is sensitized, to the patient's affected mucosal tissues, such as the nasal linings, the respiratory tract, or the eyes.

Abstract translation: 公开了含有针对豚草，房尘螨和猫和狗皮屑中发现的主要过敏原蛋白特异性的人单克隆IgA抗体的药物制剂。 还公开了包含生理相容的聚合物主链或微珠和多个共价偶联的变应原特异性结合分子的构建体。 这样的结合分子是对上述主要变应原蛋白特异的IgG或IgA或其F（ab'）2，Fab或Fv片段。 还公开了通过将患有致敏的致敏性分子的特异性抗体的药物制剂施用于患者的受影响的粘膜组织（例如鼻内衬）来治疗患有过敏性鼻炎，哮喘或结膜炎的患者的方法， 呼吸道或眼睛。

公开(公告)号：US5439665A

公开(公告)日：1995-08-08

申请号：US777499

申请日：1991-10-17

Applicant: Hans J. Hansen ,  Milton D. Goldenberg

Inventor： Hans J. Hansen ,  Milton D. Goldenberg

IPC: A61K47/48 ,  A61K51/10 ,  A61K51/00 ,  A61K39/44

CPC classification number: A61K47/48546 ,  A61K51/1018 ,  A61K2123/00

Abstract: A polyspecific anti-leukocyte antibody conjugate for targeting foci of leukocyte accretion comprises an immunoreactive polyspecific composite of at least two different substantially monospecific antibodies or antibody fragments, conjugated to at least one imaging agent, wherein at least two of said antibodies or antibody fragments specifically bind to different leukocyte cell types.A method for targeting an imaging agent to an inflammatory or infectious lesion comprises injecting a mammal parenterally with an effective amount for targeting of the above anti-leukocyte imaging conjugate.A therapeutic anti-leukocyte antibody-agent conjugate for targeting foci of leukocyte accretion comprises at least one immunoreactive substantially monospecific antibody or antibody fragment which specifically binds to at least one leukocyte cell type, conjugated to at least one therapeutic antimicrobial agent and/or radionuclide.A method of treatment of an infectious lesion comprises injecting a mammal parenterally with an effective amount for therapy of the above anti-leukocyte therapeutic conjugate.

Abstract translation: 用于靶向白细胞增生灶的多特异性抗白细胞抗体缀合物包含与至少一种成像剂缀合的至少两种不同的基本单特异性抗体或抗体片段的免疫反应性多特异性复合物，其中至少两种所述抗体或抗体片段特异性结合 到不同的白细胞类型。 用于将成像剂靶向炎性或感染性病变的方法包括以有效量肠胃外注射哺乳动物以靶向上述抗白细胞成像缀合物。 用于靶向白细胞吸积灶的治疗性抗白细胞抗体 - 试剂缀合物包含与至少一种治疗性抗微生物剂和/或放射性核素缀合的至少一种特异性结合至少一种白细胞类型的免疫反应性基本上单特异性抗体或抗体片段。 治疗感染性病变的方法包括用有效量的胃肠外注射哺乳动物治疗上述抗白细胞治疗缀合物。

公开(公告)号：US08975374B2

公开(公告)日：2015-03-10

申请号：US12584360

申请日：2009-09-03

Applicant: Naoki Kimura

Inventor： Naoki Kimura

IPC: C07K16/00

CPC classification number: C07K16/22 ,  A61K47/48546 ,  A61K47/6845 ,  A61K51/1018 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2319/30 ,  G01N33/57484

Abstract: An anti-HB-EGF antibody having an internalizing activity is disclosed. A cytotoxic substance is preferably bound to the anti-HB-EGF antibody of the present invention. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the antibody of the present invention as an active ingredient, a method of treating cancer and a method of diagnosing cancer, which comprise the administration of the antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, uterine cervical cancer, breast cancer, bladder cancer, brain tumors, and hematological cancers.

Abstract translation: 公开了具有内在活性的抗HB-EGF抗体。 细胞毒性物质优选与本发明的抗HB-EGF抗体结合。 还提供了包含本发明的抗体作为活性成分的抗癌剂和细胞增殖抑制剂，治疗癌症的方法和诊断癌症的方法，其包括施用本发明的抗体 。 可以用本发明的抗癌剂治疗的癌症包括胰腺癌，肝癌，食管癌，黑素瘤，结肠直肠癌，胃癌，卵巢癌，子宫颈癌，乳腺癌，膀胱癌，脑肿瘤和 血液癌。